2024-03-012025-02-282025-02-28false14666650FITPHARM LIMITED2025-11-30falseiso4217:GBPxbrli:pure146666502024-02-29146666502025-02-28146666502024-03-012025-02-28146666502023-02-15146666502024-02-29146666502023-02-162024-02-2914666650bus:SmallEntities2024-03-012025-02-2814666650bus:AuditExempt-NoAccountantsReport2024-03-012025-02-2814666650bus:FullAccounts2024-03-012025-02-2814666650bus:PrivateLimitedCompanyLtd2024-03-012025-02-2814666650core:WithinOneYear2025-02-2814666650core:AfterOneYear2025-02-2814666650core:WithinOneYear2024-02-2914666650core:AfterOneYear2024-02-2914666650core:ShareCapital2025-02-2814666650core:SharePremium2025-02-2814666650core:RevaluationReserve2025-02-2814666650core:OtherReservesSubtotal2025-02-2814666650core:RetainedEarningsAccumulatedLosses2025-02-2814666650core:ShareCapital2024-02-2914666650core:SharePremium2024-02-2914666650core:RevaluationReserve2024-02-2914666650core:OtherReservesSubtotal2024-02-2914666650core:RetainedEarningsAccumulatedLosses2024-02-2914666650core:LandBuildings2025-02-2814666650core:PlantMachinery2025-02-2814666650core:Vehicles2025-02-2814666650core:FurnitureFittings2025-02-2814666650core:OfficeEquipment2025-02-2814666650core:NetGoodwill2025-02-2814666650core:IntangibleAssetsOtherThanGoodwill2025-02-2814666650core:ListedExchangeTraded2025-02-2814666650core:UnlistedNon-exchangeTraded2025-02-2814666650core:LandBuildings2024-02-2914666650core:PlantMachinery2024-02-2914666650core:Vehicles2024-02-2914666650core:FurnitureFittings2024-02-2914666650core:OfficeEquipment2024-02-2914666650core:NetGoodwill2024-02-2914666650core:IntangibleAssetsOtherThanGoodwill2024-02-2914666650core:ListedExchangeTraded2024-02-2914666650core:UnlistedNon-exchangeTraded2024-02-2914666650core:LandBuildings2024-03-012025-02-2814666650core:PlantMachinery2024-03-012025-02-2814666650core:Vehicles2024-03-012025-02-2814666650core:FurnitureFittings2024-03-012025-02-2814666650core:OfficeEquipment2024-03-012025-02-2814666650core:NetGoodwill2024-03-012025-02-2814666650core:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2814666650core:ListedExchangeTraded2024-03-012025-02-2814666650core:UnlistedNon-exchangeTraded2024-03-012025-02-2814666650core:MoreThanFiveYears2024-03-012025-02-2814666650core:Non-currentFinancialInstruments2025-02-2814666650core:Non-currentFinancialInstruments2024-02-2914666650dpl:CostSales2024-03-012025-02-2814666650dpl:DistributionCosts2024-03-012025-02-2814666650core:LandBuildings2024-03-012025-02-2814666650core:PlantMachinery2024-03-012025-02-2814666650core:Vehicles2024-03-012025-02-2814666650core:FurnitureFittings2024-03-012025-02-2814666650core:OfficeEquipment2024-03-012025-02-2814666650dpl:AdministrativeExpenses2024-03-012025-02-2814666650core:NetGoodwill2024-03-012025-02-2814666650core:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2814666650dpl:GroupUndertakings2024-03-012025-02-2814666650dpl:ParticipatingInterests2024-03-012025-02-2814666650dpl:GroupUndertakingscore:ListedExchangeTraded2024-03-012025-02-2814666650core:ListedExchangeTraded2024-03-012025-02-2814666650dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-03-012025-02-2814666650core:UnlistedNon-exchangeTraded2024-03-012025-02-2814666650dpl:CostSales2023-02-162024-02-2914666650dpl:DistributionCosts2023-02-162024-02-2914666650core:LandBuildings2023-02-162024-02-2914666650core:PlantMachinery2023-02-162024-02-2914666650core:Vehicles2023-02-162024-02-2914666650core:FurnitureFittings2023-02-162024-02-2914666650core:OfficeEquipment2023-02-162024-02-2914666650dpl:AdministrativeExpenses2023-02-162024-02-2914666650core:NetGoodwill2023-02-162024-02-2914666650core:IntangibleAssetsOtherThanGoodwill2023-02-162024-02-2914666650dpl:GroupUndertakings2023-02-162024-02-2914666650dpl:ParticipatingInterests2023-02-162024-02-2914666650dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-162024-02-2914666650core:ListedExchangeTraded2023-02-162024-02-2914666650dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-162024-02-2914666650core:UnlistedNon-exchangeTraded2023-02-162024-02-2914666650core:NetGoodwill2025-02-2814666650core:IntangibleAssetsOtherThanGoodwill2025-02-2814666650core:LandBuildings2025-02-2814666650core:PlantMachinery2025-02-2814666650core:Vehicles2025-02-2814666650core:FurnitureFittings2025-02-2814666650core:OfficeEquipment2025-02-2814666650core:AfterOneYear2025-02-2814666650core:WithinOneYear2025-02-2814666650core:ListedExchangeTraded2025-02-2814666650core:UnlistedNon-exchangeTraded2025-02-2814666650core:ShareCapital2025-02-2814666650core:SharePremium2025-02-2814666650core:RevaluationReserve2025-02-2814666650core:OtherReservesSubtotal2025-02-2814666650core:RetainedEarningsAccumulatedLosses2025-02-2814666650core:NetGoodwill2024-02-2914666650core:IntangibleAssetsOtherThanGoodwill2024-02-2914666650core:LandBuildings2024-02-2914666650core:PlantMachinery2024-02-2914666650core:Vehicles2024-02-2914666650core:FurnitureFittings2024-02-2914666650core:OfficeEquipment2024-02-2914666650core:AfterOneYear2024-02-2914666650core:WithinOneYear2024-02-2914666650core:ListedExchangeTraded2024-02-2914666650core:UnlistedNon-exchangeTraded2024-02-2914666650core:ShareCapital2024-02-2914666650core:SharePremium2024-02-2914666650core:RevaluationReserve2024-02-2914666650core:OtherReservesSubtotal2024-02-2914666650core:RetainedEarningsAccumulatedLosses2024-02-2914666650core:NetGoodwill2023-02-1514666650core:IntangibleAssetsOtherThanGoodwill2023-02-1514666650core:LandBuildings2023-02-1514666650core:PlantMachinery2023-02-1514666650core:Vehicles2023-02-1514666650core:FurnitureFittings2023-02-1514666650core:OfficeEquipment2023-02-1514666650core:AfterOneYear2023-02-1514666650core:WithinOneYear2023-02-1514666650core:ListedExchangeTraded2023-02-1514666650core:UnlistedNon-exchangeTraded2023-02-1514666650core:ShareCapital2023-02-1514666650core:SharePremium2023-02-1514666650core:RevaluationReserve2023-02-1514666650core:OtherReservesSubtotal2023-02-1514666650core:RetainedEarningsAccumulatedLosses2023-02-1514666650core:AfterOneYear2024-03-012025-02-2814666650core:WithinOneYear2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:CostValuation2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2814666650core:Non-currentFinancialInstrumentscore:CostValuation2025-02-2814666650core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-2814666650core:Non-currentFinancialInstrumentscore:CostValuation2024-02-2914666650core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-2914666650core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-2914666650core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-2914666650core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-2914666650core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-2914666650core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-2914666650core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-2914666650core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-2914666650bus:Director12024-03-012025-02-2814666650core:FurnitureFittingsToolsEquipment2024-03-012025-02-2814666650core:FurnitureFittingsToolsEquipment2025-02-2814666650core:FurnitureFittingsToolsEquipment2024-02-29

FITPHARM LIMITED

Registered Number
14666650
(England and Wales)

Unaudited Financial Statements for the Year ended
28 February 2025

FITPHARM LIMITED
Company Information
for the year from 1 March 2024 to 28 February 2025

Director

GHADIMI, Arshia

Registered Address

2nd Floor Grove House
55 Lowlands Road
Harrow
HA1 3AW

Registered Number

14666650 (England and Wales)
FITPHARM LIMITED
Balance Sheet as at
28 February 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets3708,932-
Tangible assets42-
708,934-
Current assets
Stocks518,150-
Debtors6175,53643,732
Cash at bank and on hand189,795962
383,48144,694
Creditors amounts falling due within one year7(934,781)(49,517)
Net current assets (liabilities)(551,300)(4,823)
Total assets less current liabilities157,634(4,823)
Creditors amounts falling due after one year8(111,689)-
Net assets45,945(4,823)
Capital and reserves
Called up share capital100100
Profit and loss account45,845(4,923)
Shareholders' funds45,945(4,823)
The financial statements were approved and authorised for issue by the Director on 30 November 2025, and are signed on its behalf by:
GHADIMI, Arshia
Director
Registered Company No. 14666650
FITPHARM LIMITED
Notes to the Financial Statements
for the year ended 28 February 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20252024
Average number of employees during the year31
3.Intangible assets

Goodwill

Total

££
Cost or valuation
Additions766,413766,413
At 28 February 25766,413766,413
Amortisation and impairment
Charge for year57,48157,481
At 28 February 2557,48157,481
Net book value
At 28 February 25708,932708,932
At 29 February 24--
4.Tangible fixed assets

Plant & machinery

Fixtures & fittings

Total

£££
Cost or valuation
Additions112
At 28 February 25112
Net book value
At 28 February 25112
At 29 February 24---
5.Stocks

2025

2024

££
Finished goods18,150-
Total18,150-
6.Debtors: amounts due within one year

2025

2024

££
Trade debtors / trade receivables131,680-
Amounts owed by group undertakings22,54312,743
Other debtors20,77330,560
Prepayments and accrued income540429
Total175,53643,732
7.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables115,5185,324
Bank borrowings and overdrafts14,251-
Taxation and social security30,351-
Payments received on account49,162-
Other creditors725,49944,193
Total934,78149,517
8.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts111,689-
Total111,689-
9.Related party transactions
At the yearend, Fairoaks Properties Ltd owed £22,542 (2024: £12,742) to Fitpharm Limited. The companies are related as Arshia Ghadimi is also the director of this company.